NCT06129955View on ClinicalTrials.gov

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 11, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Pucotenlimab Combined With Lenvatinib

Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery

Trial Locations (1)

0755

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER